Figure 1
Figure 1. MiR-146a is upregulated upon activation of pDCs. (A) Freshly isolated pDCs or (B) CAL-1 cells were activated with the TLR9 agonists CpG-A or CpG-B, the TLR7 agonist R848 (each 10 μg/mL), IL-3 (10 ng/mL), or cultured in medium alone for 16 hours. The relative expression of the mature form of miR-146a was assessed by QPCR using specific TaqMan primers and the QPCR TaqMan kit. MiR-146a levels were normalized to the level of the small nuclear RNA U6, and the medium control condition was set to 1. Data are shown as means ± SD of independent pDC donors (CpG-A, n = 5; CpG-B, n = 4; R848, n = 5; IL-3, n = 2) or independent experiments using CAL-1 cells (CpG-A and CpG-B, n = 3; R848 and IL-3, n = 4). *P < .05.

MiR-146a is upregulated upon activation of pDCs. (A) Freshly isolated pDCs or (B) CAL-1 cells were activated with the TLR9 agonists CpG-A or CpG-B, the TLR7 agonist R848 (each 10 μg/mL), IL-3 (10 ng/mL), or cultured in medium alone for 16 hours. The relative expression of the mature form of miR-146a was assessed by QPCR using specific TaqMan primers and the QPCR TaqMan kit. MiR-146a levels were normalized to the level of the small nuclear RNA U6, and the medium control condition was set to 1. Data are shown as means ± SD of independent pDC donors (CpG-A, n = 5; CpG-B, n = 4; R848, n = 5; IL-3, n = 2) or independent experiments using CAL-1 cells (CpG-A and CpG-B, n = 3; R848 and IL-3, n = 4). *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal